Newest Viral Hepatitis Data From AASLD 2022
Listen to expert insights from Stefan Zeuzem, MD, on updates and new viral hepatitis data from AASLD 2022, including data on HBV therapy during pregnancy, HBV therapeutic vaccines and progress toward HBV cure, HDV clinical impact and phase III clinical trial updates, and HCV implementation science and HCC risk reduction with use of DAAs.
Decera Clinical Education Infectious Disease Podcast · Stefan Zeuzem MD
Audio is streamed directly from the publisher (afp-928689-injected.calisto.simplecastaudio.com) as published in their RSS feed. Play Podcasts does not host this file. Rights-holders can request removal through the copyright & takedown page.
Show Notes
In this episode, Stefan Zeuzem, MD, discusses new viral hepatitis data from AASLD 2022, including:
- Hepatitis B
- Prevention of HBV vertical transmission when HBIg is unavailable
- Therapeutic vaccination for HBV cure
- Antiviral therapy to prevent HCC in patients with CHB in the indeterminate phase
- Hepatitis delta
- HDV prevalence in ethnically diverse, urban, safety-net populations
- Bulevirtide ± pegIFN-α2a for chronic HDV in the French cATU study
- Bulevirtide monotherapy for patients with HDV and compensated cirrhosis in the HEP4Di study
- HDV functional cure with lonafarnib-based therapy
- Hepatitis C
- Integrated community HCV service for PWUD: the ITTREAT study
- Helios-3 study of treatment of people with HCV by specialists or nonspecialists
- Risk of HCC after SVR in patients with HCV
Presenter:
Stefan Zeuzem, MD
Professor of Medicine
Chief, Department of Medicine I
JW Goethe University Hospital
Frankfurt, Germany
Follow along with the downloadable slideset at:
https://bit.ly/3FxIOwZ
Link to full program:
https://bit.ly/3Y1tD6f
Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.